Neueste Forschungen über den Chromosomenbau

L. Gèitler

DOI: https://doi.org/10.1007/BF01812860

1935-11-01

Der Züchter

Abstract:

What problem does this paper attempt to address?

Amiodarone: A Comprehensive Guide for Clinicians

David Hamilton,Shuktika Nandkeolyar,Howard Lan,Pooja Desai,Jonathan Evans,Christopher Hauschild,Dimpa Choksi,Islam Abudayyeh,Tahmeed Contractor,Anthony Hilliard

DOI: https://doi.org/10.1007/s40256-020-00401-5

2020-03-13

American Journal of Cardiovascular Drugs

Abstract:Amiodarone is an effective antiarrhythmic medication frequently used in practice for both ventricular and atrial arrhythmias. Though classified as a class III antiarrhythmic, it affects all phases of the cardiac action potential. However, the drug has several side effects, including thyroid abnormalities, pulmonary fibrosis, and transaminitis, for which routine monitoring is recommended. It also interacts with several medications, such as warfarin, simvastatin, and atorvastatin, and many HIV antiretroviral medications. Given the common use of this medication in medical practice, it is vital that clinicians understand the indications, contraindications, dosing, side effects, and interactions of this medication. A thorough understanding of these topics is essential for clinicians to ensure safe and effective use of amiodarone.

pharmacology & pharmacy,cardiac & cardiovascular systems
Updated Practical Insights

Victorița Șorodoc,Lucia Indrei,Catinca Dobroghii,Andreea Asaftei,Alexandr Ceasovschih,Mihai Constantin,Cătălina Lionte,Bianca Codrina Morărașu,Alexandra-Diana Diaconu,Laurențiu Șorodoc

DOI: https://doi.org/10.3390/jcm13206094

IF: 3.9

2024-10-13

Journal of Clinical Medicine

Abstract:Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone's indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.

medicine, general & internal
Lipopeptide detergents for membrane protein studies.

G. Privé

DOI: https://doi.org/10.1016/j.sbi.2009.07.008

IF: 7.786

2009-08-01

Current Opinion in Structural Biology

Abstract:
Amiodarone: pharmacological profile, animal-model experimental data and clinical use. How important is the vasodilating effect?

A Hatzitolios,G Ntaios,C Savopoulos

Abstract:Amiodarone, the major representative of class III antiarrhythmic agents, is widely used in the treatment of ventricular and hyperventricular arrhythmias, being specifically useful in the therapy of patients suffering from life threatening ventricular arrhythmias. The combination of antianginal and antiarrthythmic actions of amiodarone is an extremely significant advantage regarding the treatment of patients with chronic atherosclerotic cardiopathy, as heart rate disorders are frequently fatal in coronary heart disease and, reversely, a high percentage of cardiac arrhythmias are caused by coronary heart disease. Since 1980s, several experimental in vitro and in vivo data, as well as clinical studies, regarding both systematic and coronary circulation, support the vasodilative effects of amiodarone. We have previously showed that amiodarone in vitro exerts a vasodilator effect in isolated vessel tissue, mainly via the activation of intracellular calcium binding mechanisms, a fact that differentiates this agent from other coronary vasodilative drugs, such as calcium channel blockers, that affect extracellular calcium ions entrance. Thus, the vasodilative, antianginal and antiarrhythmic actions of amiodarone may be further enhanced by the simultaneous supplementation of calcium channel blockers via synergistic mechanisms, supporting the clinical use of such drug combinations. Finally, as amiodarone and noradrenaline have been reported to exert antagonistic actions, the application of amiodarone is particularly indicated in pathologic conditions characterized by the stimulation of sympathetic nervous system (sympathicotonia).
Adverse effects of amiodarone therapy in adults with congenital heart disease

Benjamin M. Moore,Rachael L. Cordina,Mark A. McGuire,David S. Celermajer

DOI: https://doi.org/10.1111/chd.12657

IF: 2.419

2018-09-21

Congenital Heart Disease

Abstract:OBJECTIVE: Amiodarone is a highly effective antiarrhythmic therapy, however its toxicity profile often limits treatment. This is particularly relevant in adults with congenital heart disease (CHD), who are often young and in whom other antiarrhythmic agents commonly fail or are contraindicated. We sought to determine incidence and predictors of adverse effects caused by amiodarone in adult CHD (ACHD).DESIGN: A retrospective review of patients with moderate to complex ACHD treated with amiodarone at our center between 2000 and 2017 was performed. Incidence and predictors of adverse effects were described. Efficacy of amiodarone therapy in controlling the clinical arrhythmia was assessed as complete, partial, or failed.RESULTS: Amiodarone was prescribed in 57 patients of 902 ACHD patients reviewed (6%), for a mean duration of 2.7 ± 4.3 years. Significant adverse effects occurred in 56%, most commonly thyroid dysfunction, with amiodarone-induced thyrotoxicosis (AIT) in 30% and amiodarone-induced hypothyroidism in 14%. AIT frequently led to arrhythmia exacerbation and occurred most in those with Fontan anatomy. Severe dermatological effects were seen in 7% and bradycardia requiring pacing in 5%. Interstitial lung disease, peripheral neuropathy and alopecia were observed in single cases. Amiodarone toxicity led to discontinuation of the drug in 42%. Amiodarone was highly effective when tolerated, however, achieving complete arrhythmia control in 63%, partial control in 35%, with failure to control in only one patient.CONCLUSIONS: Amiodarone therapy is effective in moderate to complex ACHD patients, but is frequently limited by adverse effects. ACHD patients seem especially vulnerable to thyroid dysfunction, with Fontan patients in particular at increased risk of AIT.

cardiac & cardiovascular systems
The effect of amiodarone on heart rate variability in patients with idiopathic dilated cardiomyopathy

Shenwen FU,Guosheng FU

DOI: https://doi.org/10.3969/j.issn.1006-2785.2005.08.001

2005-01-01

Abstract:Objective To investigate the effects of amiodarone on heart rate variability in patients with idiopathic dilated cardiomyopathy (IDC). Methods Heart rate variability and arrhythmia on the 24h electrocardiography, EF on echocardiography were assessed in 42 IDC patients with ventricular arrhythmia before and after treatment of amiodarone. Results The antiventricular-arrhythmia effects of amiodarone were significantly higher than those of control group, and SDNN and PNN50 increased markedly after amiodarone treatment. Conclusion Amiodarone is effective and safe in treatment of IDC with arrhythmia and may improve the heart rate variability of patients.
Amiodarone-Induced Thyroid Dysfunction: A Clinical Update

Mohamed Nabil Elnaggar,Kahtan Jbeili,Nik Nik-Hussin,Mohandas Kozhippally,Joseph M Pappachan,Mohamed Elnaggar,Joseph Pappachan

DOI: https://doi.org/10.1055/a-0577-7574

2018-03-20

Abstract:Abstract Amiodarone is one of the most commonly prescribed antiarrhythmic agents in clinical practice owing to its efficacy, even with high toxicity profile. The high iodine content and the prolonged biological half-life of the drug can result in thyroid dysfunction in a high proportion of patients treated with amiodarone even after cessation of amiodarone. Both hypothyroidism and hyperthyroidism are common side effects that mandate regular monitoring of patients with thyroid function tests. Amiodarone-induced hypothyroidism (AIH) is diagnosed and managed in the same way as a usual case of hypothyroidism. However, differential diagnosis and clinical management of amiodarone-induced thyrotoxicosis (AIT) subtypes can be challenging. With the aid of a case snippet, we update the current evidence for the diagnostic work up and management of patients with amiodarone-induced thyroid dysfunction in this article.

endocrinology & metabolism
Case Report: Amiodarone-induced multi-organ toxicity

Jingrui Yan,Yuanyuan Xu,Qiang Zhu

DOI: https://doi.org/10.3389/fcvm.2024.1401049

2024-07-17

Abstract:Background: Amiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation. We present a case report of the adverse effects of amiodarone and review its characteristics. Case report: A 73-year-old Asian female with a history of paroxysmal atrial fibrillation managed with amiodarone, well-controlled hypertension, and no substance abuse presented with gastrointestinal distress and dizziness, without chest pain or palpitations. Despite normal annual check-ups, she developed abnormal liver and thyroid function tests, and imaging revealed lung and liver changes suggestive of amiodarone toxicity. Discontinuation of amiodarone for sotalol led to symptom improvement and normalization of thyroid and liver functions, with imaging indicating recovery from interstitial fibrosis and reduced liver density. Discussion: Amiodarone, a widely used for treating ventricular and atrial arrhythmias, and with significant benefits in improving patient survival in cases of ventricular fibrillation. However, its long-term use is associated with serious adverse effects, including thyroid dysfunction, liver injury, and pulmonary toxicity, necessitating careful monitoring and management. Despite its efficacy, the need for research on early detection and management of amiodarone's side effects is crucial, highlighting the importance of regular monitoring and possibly adjusting therapy to mitigate these risks.
Effects of amiodarone therapy on thyroid function

Janna Cohen-Lehman,Peter Dahl,Sara Danzi,Irwin Klein

DOI: https://doi.org/10.1038/nrendo.2009.225

2009-11-24

Nature Reviews Endocrinology

Abstract:Amiodarone is widely used for treating cardiac arrhythmias, but is associated with various adverse effects. This Review discusses how the treatment can affect thyroid function, leading to amiodarone-induced hypothyroidism or hyperthyroidism. It compares outcomes with dronedarone, a structurally similar anti-arrhythmic drug that does not contain iodine and may have fewer and less serious adverse effects.

endocrinology & metabolism
Subarachnoid hemorrhage is followed by temporomesial volume loss: MRI volumetric study

A. Rabinstein

DOI: https://doi.org/10.1212/01.wnl.0000262956.27015.9d

IF: 9.9

2006-08-22

Neurology

Abstract:Bendel et al. reported an interesting study on the volume loss of temporomesial structures after aneurysmal subarachnoid hemorrhage (SAH).1 The authors emphasize that amygdaloid atrophy was more prominent in patients treated with open surgery and provided evidence indicating that this finding may relate to retraction injury. However, hippocampal but not amygdaloid volumes correlated with deficits on neuropsychological tests. Furthermore, hippocampal volumes were unusually associated with intellectual functions other than memory. Considering these results, perhaps the authors could assess if the results of neuropsychological tests were associated with radiologically documented lesions in other brain …
Drug Interactions Affecting Antiarrhythmic Drug Use

Philip L. Mar,Piotr Horbal,Mina K. Chung,Jonathan W. Dukes,Michael Ezekowitz,Dhanunjaya Lakkireddy,Gregory Y.H. Lip,Mike Miletello,Peter A. Noseworthy,James A. Reiffel,James E. Tisdale,Brian Olshansky,Rakesh Gopinathannair,from the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology

DOI: https://doi.org/10.1161/CIRCEP.121.007955

2022-05-04

Abstract:Antiarrhythmic drugs (AAD) play an important role in the management of arrhythmias. Drug interactions involving AAD are common in clinical practice. As AADs have a narrow therapeutic window, both pharmacokinetic as well as pharmacodynamic interactions involving AAD can result in serious adverse drug reactions ranging from arrhythmia recurrence, failure of device-based therapy, and heart failure, to death. Pharmacokinetic drug interactions frequently involve the inhibition of key metabolic pathways, resulting in accumulation of a substrate drug. Additionally, over the past 2 decades, the P-gp (permeability glycoprotein) has been increasingly cited as a significant source of drug interactions. Pharmacodynamic drug interactions involving AADs commonly involve additive QT prolongation. Amiodarone, quinidine, and dofetilide are AADs with numerous and clinically significant drug interactions. Recent studies have also demonstrated increased morbidity and mortality with the use of digoxin and other AAD which interact with P-gp. QT prolongation is an important pharmacodynamic interaction involving mainly Vaughan-Williams class III AAD as many commonly used drug classes, such as macrolide antibiotics, fluoroquinolone antibiotics, antipsychotics, and antiemetics prolong the QT interval. Whenever possible, serious drug-drug interactions involving AAD should be avoided. If unavoidable, patients will require closer monitoring and the concomitant use of interacting agents should be minimized. Increasing awareness of drug interactions among clinicians will significantly improve patient safety for patients with arrhythmias.
Amiodarone (Nexterone) injection for the treatment and prophylaxis of frequently recurring ventricular fibrillation

Alessandro Marinelli,Alessandro Capucci

DOI: https://doi.org/10.1517/14656566.2012.656589

Abstract:Introduction: Intravenous (IV) amiodarone is the most used and effective drug to manage life-threatening ventricular arrhythmias. However, its administration is associated with important adverse effects, the most frequent of which is hypotension. Nexterone® is a novel IV amiodarone formulation, proved to be devoid of hypotensive effects in clinical studies and may represent an improved and safer instrument in this setting. Areas covered: The Medline Database was searched for articles on the efficacy and safety of IV amiodarone in ventricular arrhythmias and cardiac arrest. This article summarizes the key findings of the most relevant studies conducted so far, with a special attention to the limitations of the currently available IV amiodarone and the potential advantages of the recently approved Nexterone. The role given to IV amiodarone in the guidelines on Advanced Cardiovascular Life Support is also reported and discussed. Expert opinion: Available studies demonstrated a convincing efficacy of IV amiodarone in ventricular arrhythmias and cardiac arrest. The new formulation seems to resolve concerns about tolerability. However, despite proven antiarrhythmic efficacy of the drug, no improved survival was showed in different settings. The search for an antiarrhythmic drug able to impact on hard endpoint as survival to hospital discharge is therefore far from being concluded.
Pharmacotherapy in Ventricular Arrhythmias

Nachiket Apte,Dinesh K Kalra

DOI: https://doi.org/10.1159/000529670

IF: 1.9

Cardiology

Abstract:Background: Ventricular ectopy is observed in most of the population ranging from isolated premature ventricular contractions to rapid hemodynamically unstable ventricular tachyarrhythmias like ventricular tachycardia and ventricular fibrillation. Multiple mechanisms exist for ventricular arrhythmias such as triggered activity, reentry, and automaticity. Scar-based reentry forms the basis of most malignant VA that can lead to sudden cardiac death. Many antiarrhythmic drugs have been utilized for the suppression of ventricular arrhythmia. They are commonly classified using the Vaughan Williams Singh classification which distinguishes them based on the predominant action on different phases of the cardiac action potential. Class Ic agents are widely used in premature ventricular contraction suppression but are contraindicated in patients with prior myocardial infarction or ischemic scar and heart failure. β-Blockers continue to be a mainstay in the treatment of most symptomatic VA and are well tolerated, relatively safe, and have additional benefits in symptomatic coronary heart disease and left ventricular systolic dysfunction. Amiodarone continues to be used for the management of most cases of serious VA especially in the acute setting when accompanied by hemodynamic perturbations but has the disadvantage of having a poor toxicity profile for long-term use. Summary: Historically used for long-term ventricular arrhythmia suppression and prevention of sudden cardiac death, antiarrhythmics are now used to reduce implantable defibrillator shocks and symptoms. They still have a role in premature ventricular complex suppression in patients with failed catheter ablation or those who are not candidates for invasive therapy. Newer concepts in cardiac imaging and the use of artificial intelligence may help further delineate sudden cardiac risk and identify patients that may benefit from pharmacological management. Key message: Anti-arrhythmic agents continue to perform an important role in the suppression of ventricular arrhythmias especially channelopathies, polymorphic VT, and idiopathic ventricular fibrillation. Judicious use of these agents while recognizing side effects can help reduce the long-term effects of ventricular arrhythmias on cardiac function.
Amiodarone-Induced Liver Attenuation on CT Scan: Alarming Signal for Toxicity and Prompt Discontinuation

Myo Myint Tun,Sagar Pandey,Samaj Adhikari,Arjun Mainali,Ashish Thapa,Roshan Bisural,Puspa B Bista,Shwe Yee Htet,Bhawana Chhetri,Kalpana Panigrahi

DOI: https://doi.org/10.7759/cureus.39844

2023-06-01

Cureus

Abstract:Amiodarone, a class III antiarrhythmic drug, is commonly used for the management of life-threatening ventricular arrhythmias, atrial fibrillation, and other refractory supra-ventricular arrhythmias. Factors like a large volume of distribution, lipophilic property, deposition in tissues in large amounts, etc. have led to the development of amiodarone-induced multisystem adverse events. We report a case of amiodarone-induced hepatic attenuation on computed tomography (CT) of the abdomen in an elderly female patient. Amiodarone with a composition of 40% iodine by weight deposits in the liver, leading to characteristically increased radiodensity reported as increased attenuation on CT scan. Surprisingly, the severity and extent of hepatic attenuation on CT scans do not necessarily correlate with the total exposure to amiodarone over time. Individual factors may influence the liver's response to the drug, leading to varying degrees of hepatic changes. To minimize the risk of adverse events associated with amiodarone, clinicians should carefully adjust the dosage to the lowest effective level and regularly monitor liver function tests in patients. This proactive approach enables early detection of liver dysfunction and facilitates timely adjustments or discontinuation of amiodarone, thereby reducing potential harm.
Early Recanalization Postintravenous Thrombolysis in Ischemic Stroke with Large Vessel Occlusion: A Digital Subtraction Angiography Study

Yi-ting Mao,P. Mitchell,L. Churilov,R. Dowling,Q. Dong,B. Yan

DOI: https://doi.org/10.1111/cns.12549

2016-05-01

CNS Neuroscience & Therapeutics

Abstract:We aimed to evaluate early recanalization postintravenous (i.v.) tissue plasminogen activator (t‐PA) by digital subtraction angiography (DSA) in acute ischemic stroke (AIS) with large vessel occlusion (LVO).
Sci-Sat AM(2): Brachy-08: Monte Carlo calculations of 192Ir high dose rate brachytherapy treatment plans using CT and cone beam CT images.

E. Poon,F. Verhaegen

DOI: https://doi.org/10.1118/1.2966000

2008-07-01

Abstract:The feasibility of using cone beam computed tomography (CBCT) images for Monte Carlo (MC) brachytherapy dose calculations has been investigated. To evaluate the effects of tissue heterogeneities and finite patient dimensions for 192Ir high dose rate treatment, CT-based MC calculations for breast and head and neck cases were first performed using the PTRAN_CT photon transport code. PTRAN_CT is an accelerated MC code specifically designed for patient-specific dose calculations. Muscles and adipose tissues, which are nearly indistinguishable in CBCT images, are found to cause minimal dose perturbations at 192Ir energies compared to water. The proximity of the tumor to the skin, however, will have an observable impact on the dose up to a few percent. Therefore, for CBCT calculations, a reasonable assignment of material and density values to the patient voxel geometry, with a good delineation of the skin and bony structures, will suffice for MC dose calculations. A CBCT-based calculation for an actual treatment plan with the tumor close to the cheek was performed. The results were compared to TG43 calculations to quantify the dose differences in the target and critical structures. Since the dose delivered to the tumor is mostly primary dose, deviations are found mostly in the organs at risk where scatter contribution becomes more significant. This study shows that for HDR brachytherapy applications, CBCT-based MC calculations is a feasible option despite inferior image quality and larger uncertainties in the Hounsfield Units compared to CT images. Research supported by Nucletron BV.
Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits

John Camm

DOI: https://doi.org/10.1016/j.ijcard.2011.06.012

2012-03-22

Abstract:Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice, and its complications impose a significant economic burden. The development of more effective agents to manage patients with AF is essential. While clinical trials show no major differences in outcomes between rate and rhythm control strategies, some patients with AF require treatment with antiarrhythmic drugs (AADs) to maintain sinus rhythm, reduce symptoms, improve exercise tolerance, and improve quality of life. Currently available AADs, while effective, have limitations including limited efficacy, adverse events, toxicity, and proarrhythmic potential. The 6 most commonly used AADs (amiodarone, disopyramide, dofetilide [USA but not Europe], flecainide, propafenone, sotalol) have proarrhythmic effects (fewer with amiodarone). Amiodarone is the most effective AAD, but its safety profile limits its usefulness. Recent advances in AAD therapy include dronedarone and vernakalant. Dronedarone, approved by the United States Food and Drug Administration and the European Medicines Authority and others, has been proven efficacious in maintaining sinus rhythm and reducing the incidence of hospitalization due to cardiovascular events or death in patients with AF. The intravenous formulation of vernakalant is approved in the European Union, Iceland, and Norway. Oral vernakalant is currently undergoing evaluation for preventing AF recurrence and appears to be effective with an acceptable safety profile. Treatment should be individualized to the patient with consideration of pharmacologic risks and benefits according to AF management guidelines. Accumulating efficacy and safety data for new and emerging AADs holds promise for improved AF management and outcomes.
Atrial fibrillation: choosing an antiarrhythmic drug

Todd Rudo,Peter Kowey

DOI: https://doi.org/10.1007/s11886-006-0077-z

Abstract:Atrial fibrillation is the most common arrhythmia encountered in clinical practice. The associated hemodynamic changes can lead to symptoms of palpitations, fatigue, light-headedness, or dyspnea. Extensive research in the use of antiarrhythmic drugs has been performed both to facilitate the conversion of atrial fibrillation to sinus rhythm and to maintain normal sinus rhythm. The relative merits of a rhythm control versus rate control strategy are briefly discussed. Efficacy of the available agents for pharmacologic cardioversion is reviewed in detail. Important drugs for maintenance of sinus rhythm include amiodarone, flecainide, propafenone, sotalol, and dofetilide. Selection of the appropriate antiarrhythmic drug must be individualized to the clinical situation, with Class IC drugs being first-line agents in the absence of structural heart disease. Regardless of agent selected, appropriate monitoring for development of adverse effects is of utmost importance.
Amiodarone-induced hepatic injury

Qiufen Xie,Qian Xiang,Ying Zhou,Yimin Cui

DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2014.06.010

2014-01-01

Abstract:Amiodarone,one of Class Ⅲ antiarrhythmic drugs,may lead to hepatic injury,the incidence of which is about 14% to 82% . Clinical manifestations differ widely from asymptomatic elevated liver enzymes to fulminant hepatic failure and even death. Histopathological findings are similar to those of alcoholic liver disease and characterized by lysosomes phospholipidosis and granular cells. Pathogenesis includes toxicity of amiodarone and its major metabolite,immunological mechanisms,and genetic factors. Intravenous AIHI is mainly related to the effect of cosolvent,polysorbate 80. Men,heart failure and plasma concentration >2.5 mg/ L may be risk factors. Indications to use amiodarone should be strictly controlled and patients' physical conditions should be considered for choosing methods of administration. Monitoring closely is needed for liver function and/ or blood concentration during treatment. When liver function is abnormal, weigh the benefits and risks of treatment carefully,and decide whether dosage reduction or withdrawal of the drug is necessary.
Pediatric use of intravenous amiodarone: Efficacy and safety in critically III patients from a multicenter protocol

James C. Perry,Arnold L. Fenrich,J. Edward Hulse,John K. Trienman,Richard A. Friedman,John J. Lamberti

DOI: https://doi.org/10.1016/0735-1097(95)00591-9

IF: 24

1996-04-01

Journal of the American College of Cardiology

Abstract:OBJECTIVE: The purpose of this study was to analyze the efficacy and safety of intravenous amiodarone in young patients with critical, drug-resistant arrhythmias.BACKGROUND: Intravenous amiodarone has been investigated in adults since the early 1980s. Experience with the drug in young patients is limited. A larger pediatric study group was necessary to provide responsible guidelines for the drug's use before its market release.METHODS: Eight centers obtained institutional approval of a standardized protocol. Other centers were approved on a compassionate use basis after contacting the primary investigator (J.C.P).RESULTS: Forty patients were enrolled. Standard management in all failed. Many patients had early postoperative tachyarrhythmias (25 of 40), with early successful treatment in 21 (84%) of 25. Twelve patients had ventricular tachyarrhythmias: seven had successful therapy, and six died, none related to the drug. Eleven patients had atrial tachyarrhythmias: 10 of 11 had immediate success, but 3 later died. Fourteen patients had junctional ectopic tachycardia, which was treated with success (sinus rhythm or slowing, allowing pacing) in 13 of 14, with no deaths. Three other patients had supraventricular tachycardias, with success in two and no deaths. The average loading dose was 6.3 mg/kg body weight, and 50% of patients required a continuous infusion. Four patients had mild hypotension during the amiodarone bolus. One postoperative patient experienced bradycardia requiring temporary pacing. There were no proarrhythmic effects. Deaths (9 [23%] of 40) were not attributed to amiodarone.CONCLUSIONS: Intravenous amiodarone is safe and effective in most young patients with critical tachyarrhythmia. Intravenous amiodarone can be lifesaving, particularly for postoperative junctional ectopic tachycardia, when standard therapy is ineffective.

cardiac & cardiovascular systems

Neueste Forschungen über den Chromosomenbau

Amiodarone: A Comprehensive Guide for Clinicians

Updated Practical Insights

Lipopeptide detergents for membrane protein studies.

Amiodarone: pharmacological profile, animal-model experimental data and clinical use. How important is the vasodilating effect?

Adverse effects of amiodarone therapy in adults with congenital heart disease

The effect of amiodarone on heart rate variability in patients with idiopathic dilated cardiomyopathy

Amiodarone-Induced Thyroid Dysfunction: A Clinical Update

Case Report: Amiodarone-induced multi-organ toxicity

Effects of amiodarone therapy on thyroid function

Subarachnoid hemorrhage is followed by temporomesial volume loss: MRI volumetric study

Drug Interactions Affecting Antiarrhythmic Drug Use

Amiodarone (Nexterone) injection for the treatment and prophylaxis of frequently recurring ventricular fibrillation

Pharmacotherapy in Ventricular Arrhythmias

Amiodarone-Induced Liver Attenuation on CT Scan: Alarming Signal for Toxicity and Prompt Discontinuation

Early Recanalization Postintravenous Thrombolysis in Ischemic Stroke with Large Vessel Occlusion: A Digital Subtraction Angiography Study

Sci-Sat AM(2): Brachy-08: Monte Carlo calculations of 192Ir high dose rate brachytherapy treatment plans using CT and cone beam CT images.

Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits

Atrial fibrillation: choosing an antiarrhythmic drug

Amiodarone-induced hepatic injury

Pediatric use of intravenous amiodarone: Efficacy and safety in critically III patients from a multicenter protocol